Motilal Oswal's research report on SBI Life Insurance
SBILIFE reported a strong 2QFY22, with APE growth of 46% YoY (5% beat) and VNB growth at a stellar 91% YoY (10% beat). VNB margin improved to 25.9% (up ~560bp YoY). However, shareholders’ PAT declined by ~18% YoY on account of higher claims settled in 2QFY22. Among segments, ULIP saw a strong rebound, up 67% YoY. NonPAR/Protection grew better than its peers, up 68%/21% YoY. Persistency has improved across cohorts, with 13th month persistency improving by ~180bp YoY to 87.7% and steady trends in the 61st month at 60.7%. We estimate 23% CAGR in APE over FY21-24E. VNB margin is estimated to reach 26.2% by FY24E, thus enabling 28% VNB CAGR and ~18% EV CAGR over FY21-24E. We maintain our Buy rating.
Outlook
We maintain our Buy rating with a revised TP of INR1,500/share (2.7x Sep’23E EV).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
